CERS Stock - Cerus Corporation
Unlock GoAI Insights for CERS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $180.27M | $156.37M | $162.05M | $130.86M | $91.92M |
| Gross Profit | $99.52M | $86.40M | $87.09M | $67.38M | $50.76M |
| Gross Margin | 55.2% | 55.3% | 53.7% | 51.5% | 55.2% |
| Operating Income | $-14,225,000 | $-30,053,000 | $-34,081,000 | $-48,936,000 | $-58,333,000 |
| Net Income | $-20,918,000 | $-37,489,000 | $-42,779,000 | $-54,374,000 | $-59,857,000 |
| Net Margin | -11.6% | -24.0% | -26.4% | -41.6% | -65.1% |
| EPS | $-0.11 | $-0.21 | $-0.24 | $-0.32 | $-0.37 |
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 12th 2024 | Craig Hallum | Initiation | Buy | $5 |
| January 20th 2023 | BTIG Research | Downgrade | Neutral | - |
| January 17th 2023 | Stephens | Downgrade | Equal Weight | $3.75 |
Earnings History & Surprises
CERSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | $-0.01 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.02 | $-0.00 | +99.5% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.02 | $-0.03 | -50.0% | ✗ MISS |
Q2 2025 | May 1, 2025 | $-0.05 | $-0.04 | +20.0% | ✓ BEAT |
Q1 2025 | Feb 20, 2025 | $-0.01 | $-0.01 | 0.0% | = MET |
Q4 2024 | Oct 30, 2024 | $-0.01 | $-0.02 | -33.3% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-0.02 | $-0.03 | -25.0% | ✗ MISS |
Q2 2024 | May 2, 2024 | $-0.05 | $-0.05 | -7.1% | ✗ MISS |
Q1 2024 | Mar 5, 2024 | $-0.01 | $-0.01 | -58.2% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.05 | $-0.03 | +40.0% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $-0.05 | $-0.07 | -40.0% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.05 | $-0.09 | -80.0% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $-0.05 | $-0.08 | -68.4% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-0.05 | $-0.05 | 0.0% | = MET |
Q3 2022 | Aug 4, 2022 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.10 | $-0.07 | +30.0% | ✓ BEAT |
Q1 2022 | Feb 22, 2022 | $-0.08 | $-0.05 | +37.5% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $-0.10 | $-0.07 | +30.0% | ✓ BEAT |
Q3 2021 | Aug 3, 2021 | $-0.10 | $-0.09 | +10.0% | ✓ BEAT |
Latest News
Cerus To Partner With Blood Centers Of America To Drive Expanded Access To Pathogen Reduction Technology For INTERCEPT Fibrinogen Complex Across Blood Center Membership
📈 PositiveCORRECTION: Cerus Q3 EPS $0.00 Beats $(0.03) Estimate, Sales $52.698M Miss $54.400M Estimate
➖ NeutralCerus Raises FY2025 Sales Guidance from $200.000M-$203.000M to $202.000M-$204.000M vs $210.433M Est
📉 NegativeCerus Q3 EPS $(0.02) Beats $(0.03) Estimate, Sales $52.698M Miss $54.400M Estimate
➖ NeutralCerus Corporation Announces German Blood Advisory Committee's Recommendation Of INTERCEPT For Enhanced Platelet Transfusion Safety
📈 PositiveFrequently Asked Questions about CERS
What is CERS's current stock price?
What is the analyst price target for CERS?
What sector is Cerus Corporation in?
What is CERS's market cap?
Does CERS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CERS for comparison